NASDAQ:ITCI

Intra-Cellular Therapies Competitors

$29.62
-0.94 (-3.08 %)
(As of 04/21/2021 02:27 PM ET)
Add
Compare
Today's Range
$29.30
Now: $29.62
$30.36
50-Day Range
$30.13
MA: $33.48
$36.98
52-Week Range
$16.14
Now: $29.62
$40.01
Volume9,997 shs
Average Volume599,557 shs
Market Capitalization$2.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.5

Competitors

Intra-Cellular Therapies (NASDAQ:ITCI) Vs. JAZZ, UTHR, MRVI, BBIO, MRTX, and ARWR

Should you be buying ITCI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Intra-Cellular Therapies, including Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), and Arrowhead Pharmaceuticals (ARWR).

Intra-Cellular Therapies (NASDAQ:ITCI) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Intra-Cellular Therapies and Jazz Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0039,946.03$-147,720,000.00($2.68)-11.05
Jazz Pharmaceuticals$2.16 billion4.41$523.37 million$14.6011.60

Jazz Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intra-Cellular Therapies and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
Jazz Pharmaceuticals7.86%20.16%10.85%

Analyst Recommendations

This is a summary of recent recommendations for Intra-Cellular Therapies and Jazz Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
Jazz Pharmaceuticals111702.84

Intra-Cellular Therapies currently has a consensus price target of $47.4286, indicating a potential upside of 61.32%. Jazz Pharmaceuticals has a consensus price target of $187.3684, indicating a potential upside of 11.16%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, equities analysts clearly believe Intra-Cellular Therapies is more favorable than Jazz Pharmaceuticals.

Risk & Volatility

Intra-Cellular Therapies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Intra-Cellular Therapies on 9 of the 14 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and United Therapeutics (NASDAQ:UTHR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Profitability

This table compares Intra-Cellular Therapies and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
United Therapeutics33.25%15.48%11.31%

Analyst Ratings

This is a summary of current ratings and recommmendations for Intra-Cellular Therapies and United Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
United Therapeutics00703.00

Intra-Cellular Therapies currently has a consensus target price of $47.4286, suggesting a potential upside of 61.32%. United Therapeutics has a consensus target price of $219.5714, suggesting a potential upside of 4.25%. Given Intra-Cellular Therapies' higher probable upside, research analysts plainly believe Intra-Cellular Therapies is more favorable than United Therapeutics.

Earnings & Valuation

This table compares Intra-Cellular Therapies and United Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0039,946.03$-147,720,000.00($2.68)-11.05
United Therapeutics$1.45 billion6.48$-104,500,000.00($2.39)-88.24

United Therapeutics has higher revenue and earnings than Intra-Cellular Therapies. United Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intra-Cellular Therapies has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Institutional and Insider Ownership

79.1% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 90.1% of United Therapeutics shares are owned by institutional investors. 18.2% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 10.9% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

United Therapeutics beats Intra-Cellular Therapies on 8 of the 12 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Valuation & Earnings

This table compares Maravai LifeSciences and Intra-Cellular Therapies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Intra-Cellular Therapies$60,000.0039,946.03$-147,720,000.00($2.68)-11.05

Maravai LifeSciences has higher earnings, but lower revenue than Intra-Cellular Therapies.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Maravai LifeSciences and Intra-Cellular Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Intra-Cellular Therapies00703.00

Maravai LifeSciences currently has a consensus price target of $38.1250, suggesting a potential upside of 6.79%. Intra-Cellular Therapies has a consensus price target of $47.4286, suggesting a potential upside of 61.32%. Given Intra-Cellular Therapies' higher probable upside, analysts plainly believe Intra-Cellular Therapies is more favorable than Maravai LifeSciences.

Profitability

This table compares Maravai LifeSciences and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Insider & Institutional Ownership

79.1% of Intra-Cellular Therapies shares are owned by institutional investors. 18.2% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BridgeBio Pharma (NASDAQ:BBIO) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BridgeBio Pharma and Intra-Cellular Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma01902.90
Intra-Cellular Therapies00703.00

BridgeBio Pharma currently has a consensus target price of $72.8889, indicating a potential upside of 33.64%. Intra-Cellular Therapies has a consensus target price of $47.4286, indicating a potential upside of 61.32%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Intra-Cellular Therapies is more favorable than BridgeBio Pharma.

Earnings & Valuation

This table compares BridgeBio Pharma and Intra-Cellular Therapies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million201.62$-260,590,000.00($2.48)-22.14
Intra-Cellular Therapies$60,000.0039,946.03$-147,720,000.00($2.68)-11.05

Intra-Cellular Therapies has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Profitability

This table compares BridgeBio Pharma and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/A-109.88%-48.54%
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Summary

Intra-Cellular Therapies beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

Mirati Therapeutics (NASDAQ:MRTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by company insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Mirati Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Earnings and Valuation

This table compares Mirati Therapeutics and Intra-Cellular Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,419.37$-213,260,000.00($5.69)-28.05
Intra-Cellular Therapies$60,000.0039,946.03$-147,720,000.00($2.68)-11.05

Intra-Cellular Therapies has lower revenue, but higher earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirati Therapeutics and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Mirati Therapeutics and Intra-Cellular Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics151002.56
Intra-Cellular Therapies00703.00

Mirati Therapeutics currently has a consensus target price of $218.5714, indicating a potential upside of 37.61%. Intra-Cellular Therapies has a consensus target price of $47.4286, indicating a potential upside of 61.32%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Intra-Cellular Therapies is more favorable than Mirati Therapeutics.

Summary

Intra-Cellular Therapies beats Mirati Therapeutics on 9 of the 14 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Intra-Cellular Therapies and Arrowhead Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0039,946.03$-147,720,000.00($2.68)-11.05
Arrowhead Pharmaceuticals$87.99 million80.99$-84,550,000.00($0.84)-81.74

Arrowhead Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intra-Cellular Therapies and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Volatility and Risk

Intra-Cellular Therapies has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Intra-Cellular Therapies and Arrowhead Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
Arrowhead Pharmaceuticals021002.83

Intra-Cellular Therapies presently has a consensus price target of $47.4286, indicating a potential upside of 61.32%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, indicating a potential upside of 25.29%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, research analysts plainly believe Intra-Cellular Therapies is more favorable than Arrowhead Pharmaceuticals.

Insider & Institutional Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Intra-Cellular Therapies on 8 of the 14 factors compared between the two stocks.


Intra-Cellular Therapies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$169.31-0.7%$9.47 billion$2.16 billion53.41Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$210.89-1.6%$9.25 billion$1.45 billion19.95
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.86-1.0%$9.14 billionN/A0.00Increase in Short Interest
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.90-1.4%$8.27 billion$40.56 million-16.10
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$159.59-2.4%$7.89 billion$3.34 million-20.73
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$68.66-0.8%$7.07 billion$87.99 million-81.74
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$108.01-2.8%$7.03 billion$103.71 million-24.60Analyst Report
Insider Selling
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.37-0.0%$6.85 billion$311.33 million-126.96News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$124.74-0.2%$6.72 billion$14.98 million-15.19Unusual Options Activity
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.56-1.0%$5.80 billion$1.12 billion86.58Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.34-1.4%$5.66 billion$380.83 million-9.25Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.57-1.5%$5.62 billion$150,000.00-19.14Analyst Report
Analyst Revision
News Coverage
Gap Up
Perrigo logo
PRGO
Perrigo
2.3$42.57-1.2%$5.62 billion$4.84 billion-709.38Dividend Announcement
Allakos logo
ALLK
Allakos
1.7$106.17-1.9%$5.57 billionN/A-38.75
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.84-1.3%$5.37 billion$66.51 million17.31Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.74-3.7%$5.22 billion$1.00 billion-12.54Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.5$72.46-3.4%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.50-1.1%$4.57 billionN/A-6.07Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.02-0.8%$4.29 billion$6.87 million-7.15Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.79-2.7%$4.22 billion$204.89 million-37.24
I-Mab logo
IMAB
I-Mab
1.4$55.33-2.7%$4.09 billion$4.31 million-1.91
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.83-1.6%$4.03 billion$806.43 million-9.61Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.04-1.2%$3.89 billion$117.91 million-11.16
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.95-0.1%$3.70 billionN/A-6.19
LEGN
Legend Biotech
1.2$27.21-1.8%$3.55 billion$64.39 million0.00Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$66.00-0.6%$3.52 billion$1.11 billion21.22News Coverage
Gap Up
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.32-2.4%$3.50 billionN/A-20.89
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$40.95-3.4%$3.50 billionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.72-4.6%$3.43 billion$114.62 million-7.95
Insmed logo
INSM
Insmed
1.2$33.57-3.8%$3.34 billion$136.47 million-12.91
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.42-2.9%$3.33 billion$339.08 million-12.45Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$45.73-1.3%$3.26 billion$306.98 million-6.54
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.73-1.6%$3.23 billion$26.52 million-7.99Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.53-1.8%$3.21 billion$1.17 billion-44.63Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.05-1.7%$3.16 billion$36.13 million-68.73
Arvinas logo
ARVN
Arvinas
1.5$65.73-5.8%$3.03 billion$42.98 million-25.68Upcoming Earnings
Analyst Report
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.1%$2.96 billion$80.43 million108.34
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$108.36-0.3%$2.92 billionN/A-53.91News Coverage
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$76.68-0.9%$2.91 billion$644.77 million-10.94
OPKO Health logo
OPK
OPKO Health
1.9$4.27-3.3%$2.77 billion$901.90 million-23.72
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$64.14-2.3%$2.75 billion$421.03 million22.58News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.43-1.0%$2.65 billion$25 million-9.09Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.02-2.1%$2.64 billion$306.49 million25.87
Organogenesis logo
ORGO
Organogenesis
1.0$21.21-3.3%$2.62 billion$260.98 million-353.50News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.94-1.5%$2.61 billionN/A-23.59
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.89-1.1%$2.59 billion$182.24 million-8.60Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.08-1.9%$2.57 billion$2.11 million-9.11Analyst Report
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.54-2.5%$2.44 billion$120.28 million-152.06Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.07-1.3%$2.41 billion$156.70 million-30.05
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.49-3.3%$2.32 billion$23.90 million-18.32Analyst Report
Insider Selling
Analyst Revision
News Coverage
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.